title: Pseudohypoparathyroidism Ia and hypercalcitoninemia.
abstract: Pseudohypoparathyroidism Ia (PHP Ia) is characterized by resistance to PTH and many other stimuli because of deficiency of stimulatory G protein alpha-subunit. To determine the incidence, natural history, and mechanism of C cell dysfunction in PHP, calcitonin assays were performed in six patients with PHP Ia and four with pseudopseudohypoparathyroidism from three unrelated families. Controls included healthy subjects and patients with PHP Ib or hypoparathyroidism. The mean basal level of calcitonin was higher in PHP Ia patients than in controls (95.3 +/- 112.7 vs. 3.7 +/- 2.4 pg/mL; P = 0.005; n < 10). In PHP Ia patients, calcitonin levels rose over the normal range (30 pg/mL) after pentagastrin infusion in five patients and remained normal in one. Familial medullary thyroid carcinoma was clinically, biologically, and ultrasonographically ruled out over a mean follow-up exceeding 3 yr. Genomic screening for RET protooncogene mutations failed to reveal any anomaly. The calcitonin infusion test, which induced a significant increase in plasma cAMP in controls 30 and 60 min after infusion, failed to produce this response in PHP Ia patients, suggesting that the action of calcitonin was specifically impaired. PHP Ia may therefore be an independent etiology of hypercalcitoninemia and hyperresponsiveness to pentagastrin infusion.
authors.affiliation: Service de Médecine Interne et Endocrinologie, CHU de Lille, 59037 Lille, France. virginie.vlaeminck@wanadoo.fr
authors.forename: V
authors.initials: V
authors.lastname: Vlaeminck-Guillem
authors.forename: M
authors.initials: M
authors.lastname: D'herbomez
authors.forename: P
authors.initials: P
authors.lastname: Pigny
authors.forename: A
authors.initials: A
authors.lastname: Fayard
authors.forename: C
authors.initials: C
authors.lastname: Bauters
authors.forename: M
authors.initials: M
authors.lastname: Decoulx
authors.forename: J L
authors.initials: JL
authors.lastname: Wémeau
mesh_terms: D000328:Adult; D002116:Calcitonin / Q000097:blood*; D018276:Carcinoma, Medullary / Q000235:genetics; D000242:Cyclic AMP / Q000097:blood; D029721:Drosophila Proteins; D005260:Female; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000097:blood; D006801:Humans; D007011:Hypoparathyroidism / Q000097:blood; D008297:Male; D009154:Mutation; D010418:Pentagastrin; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051096:Proto-Oncogene Proteins c-ret; D011547:Pseudohypoparathyroidism / Q000097:blood / Q000235:genetics / Q000503:physiopathology*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D013964:Thyroid Neoplasms / Q000235:genetics; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D029721:Drosophila Proteins; D011518:Proto-Oncogene Proteins; D014284:Triiodothyronine; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D002116:Calcitonin; D000242:Cyclic AMP; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases; C416649:Ret protein, Drosophila; D019205:GTP-Binding Protein alpha Subunits, Gs; D010418:Pentagastrin; D013974:Thyroxine